A citation-based method for searching scientific literature

Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List. BMC Med 2013
Times Cited: 201



J P H Wilding, V Woo, K Rohwedder, J Sugg, S Parikh. Diabetes Obes Metab 2014
Times Cited: 182




List of shared articles



Times cited

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes.
Jamie L Benham, Jane E Booth, Ronald J Sigal, Stella S Daskalopoulou, Alexander A Leung, Doreen M Rabi. Int J Cardiol Heart Vasc 2021
2

Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
Daobo Li, Yingying Liu, Tesfaldet Habtemariam Hidru, Xiaolei Yang, Yunsong Wang, Cheng Chen, Ka Hou Christien Li, Yuqi Tang, Yushan Wei, Gary Tse,[...]. Front Endocrinol (Lausanne) 2021
1

SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Nanjing Shi, Yetan Shi, Jingsi Xu, Yuexiu Si, Tong Yang, Mengting Zhang, Derry Minyao Ng, Xiangyuan Li, Fei Xie. Front Public Health 2021
0

Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.
Martha K Nicholson, Randa Ghazal Asswad, John Ph Wilding. Expert Opin Pharmacother 2021
0

Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression.
Ayodele Odutayo, Bruno R da Costa, Tiago V Pereira, Vinay Garg, Samir Iskander, Fatimah Roble, Rahim Lalji, Cesar A Hincapié, Aquila Akingbade, Myanca Rodrigues,[...]. J Am Heart Assoc 2021
0

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
Nienke M A Idzerda, Bergur V Stefansson, Michelle J Pena, David C Sjostrom, David C Wheeler, Hiddo J L Heerspink. Nephrol Dial Transplant 2020
6


Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement.
Tae Jung Oh, Ju Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon. Diabetes Metab J 2020
0

Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement.
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon. Kidney Res Clin Pract 2020
0

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini. Cardiovasc Diabetol 2020
9

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.
Maria J Pereira, Jan W Eriksson. Drugs 2019
48

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen,[...]. BMJ Open 2019
62

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials.
Ilaria Dicembrini, Besmir Nreu, Edoardo Mannucci, Matteo Monami. Diabetes Obes Metab 2019
18

Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population.
Rana Moustafa Al AdAwi, Zainab Jassim, Dina Elgaily, Hani Abdelaziz, Bhagya Sree, Mohamed Izham Mohamed Ibrahim. Sci Rep 2019
4

Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.
Ilaria Dicembrini, Benedetta Tomberli, Besmir Nreu, Giorgio Iacopo Baldereschi, Fabrizio Fanelli, Edoardo Mannucci, Matteo Monami. Diabetes Res Clin Pract 2019
15

Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials.
Robert D Toto, Ronald Goldenberg, Glenn M Chertow, Valerie Cain, Bergur V Stefánsson, C David Sjöström, Peter Sartipy. J Diabetes Complications 2019
6

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou, Nikolaos Tentolouris. Int J Environ Res Public Health 2019
46

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Serge Jabbour, Jochen Seufert, Andre Scheen, Clifford J Bailey, Cathrina Karup, Anna M Langkilde. Diabetes Obes Metab 2018
78

Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials.
Matteo Monami, Francesco Liistro, Alessia Scatena, Besmir Nreu, Edoardo Mannucci. Diabetes Obes Metab 2018
15


Recent progress of sodium-glucose transporter 2 inhibitors as potential antidiabetic agents.
Yajing Zhang, Huazhuo Ban, Runan Yu, Zhijian Wang, Dayong Zhang. Future Med Chem 2018
6

Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany.
Matthew Hankins, Katherine Tsai, Joseph Kim, Niklas Hammar. Diabetes Res Clin Pract 2017
3


A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
A Avogaro, A Giaccari, P Fioretto, S Genovese, F Purrello, F Giorgino, S Del Prato. Expert Rev Clin Pharmacol 2017
10